Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
The present invention is directed to (S)-(−)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride dihydrate, to a method producing the dihydrate, and to a drug composition containing the dihydrate. The compound of the present invention has less hygroscopicity as compared with (S)-(−)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride anhydrous crystals and thus, exhibits excellent chemical stability.
patent: 6153608 (2000-11-01), Hidaka et al.
patent: 9 12573 (1997-01-01), None
patent: 97 02260 (1997-01-01), None
patent: 99 20620 (1999-04-01), None
patent: WO 99/20620 (1999-04-01), None
Coleman Brenda L
D. Western Therapeutics Institute, Inc.
Kowa Co. Ltd.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
(S)-(-)-1-(4-fluoroisoquinolin-5-Yl)Sulfonyl-2-methyl-1,4-ho... does not yet have a rating. At this time, there are no reviews or comments for this patent.If you have personal experience with (S)-(-)-1-(4-fluoroisoquinolin-5-Yl)Sulfonyl-2-methyl-1,4-ho..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (S)-(-)-1-(4-fluoroisoquinolin-5-Yl)Sulfonyl-2-methyl-1,4-ho... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4217208